2025/02/05 by Alison M. Schram, Kōichi Goto, Dong-Wan Kim +29 · 1 voice · 2 citations
Medicine · #HER2/EGFR in Cancer Research #Thyroid Cancer Diagnosis and Treatment #Neuroendocrine Tumor Research Advances
paper · doi:10.1056/nejmoa2405008
openalex publication_date 2025/02/05 · openalex created_date 2025/02/05 · openalex updated_date 2026/07/31
BACKGROUND: fusion-positive solid tumors are unclear. METHODS: fusion-positive cancer involving any tumor type to receive zenocutuzumab at a dose of 750 mg intravenously every 2 weeks. The primary end point was overall response (complete or partial response) according to investigator assessment. Secondary end points included duration of response, progression-free survival, and safety. RESULTS: fusion partners. The median progression-free survival was 6.8 months (95% CI, 5.5 to 9.1). Adverse events were primarily grade 1 or 2. The most common adverse events that were considered by the investigator to be related to zenocutuzumab were diarrhea (in 18% of the patients), fatigue (in 12%), and nausea (in 11%). Infusion-related reactions (composite term) were observed in 14% of the patients. One patient discontinued zenocutuzumab owing to a treatment-related adverse event. CONCLUSIONS: fusion-positive cancer, notably NSCLC and pancreatic cancer, with mainly low-grade adverse events. (Funded by Merus; eNRGy ClinicalTrials.gov number, NCT02912949.).